Atara Biotherapeutics, Inc. (ATRA) stock
ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$6.33−0.01 (-0.16%)
Close on Nov 20, 2026Market cap $63.54MP/E –Yield –
Atara Biotherapeutics shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Atara Biotherapeutics's shares outstanding was 15M at Jun 30, 2026. For fiscal 2025 it was 13M, up 69.8% from the year before. Over ten years it grew 28.7% a year on average. The highest annual figure on record is 13M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13M | +69.8% |
| FY2024 | Dec 31, 2024 | 7M | +76.8% |
| FY2023 | Dec 31, 2023 | 4M | +3.8% |
| FY2022 | Dec 31, 2022 | 4M | +8.9% |
| FY2021 | Dec 31, 2021 | 4M | +26.6% |
| FY2020 | Dec 31, 2020 | 3M | +44.2% |
| FY2019 | Dec 31, 2019 | 2M | +17.1% |
| FY2018 | Dec 31, 2018 | 2M | +46.7% |
| FY2017 | Dec 31, 2017 | 1M | +3.9% |
| FY2016 | Dec 31, 2016 | 1M | +12.3% |
| FY2015 | Dec 31, 2015 | 1M | +413.1% |
| FY2014 | Dec 31, 2014 | 0M | +416.2% |
| FY2013 | Dec 31, 2013 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 15M | +22.1% |
| Q1 FY2026 | Mar 31, 2026 | 14M | +29.8% |
| Q4 FY2025 | Dec 31, 2025 | 14M | +29.9% |
| Q3 FY2025 | Sep 30, 2025 | 14M | +81.7% |
| Q2 FY2025 | Jun 30, 2025 | 12M | +100.4% |
| Q1 FY2025 | Mar 31, 2025 | 11M | +93.0% |
| Q4 FY2024 | Dec 31, 2024 | 11M | +147.7% |
| Q3 FY2024 | Sep 30, 2024 | 7M | +75.4% |
| Q2 FY2024 | Jun 30, 2024 | 6M | +46.1% |
| Q1 FY2024 | Mar 31, 2024 | 6M | +35.2% |
| Q4 FY2023 | Dec 31, 2023 | 4M | +4.7% |
| Q3 FY2023 | Sep 30, 2023 | 4M | +3.9% |
| Q2 FY2023 | Jun 30, 2023 | 4M | +3.2% |
| Q1 FY2023 | Mar 31, 2023 | 4M | +3.2% |
| Q4 FY2022 | Dec 31, 2022 | 4M | +5.9% |
| Q3 FY2022 | Sep 30, 2022 | 4M | +9.4% |
| Q2 FY2022 | Jun 30, 2022 | 4M | +10.5% |
| Q1 FY2022 | Mar 31, 2022 | 4M | +10.1% |
| Q4 FY2021 | Dec 31, 2021 | 4M | +14.1% |
| Q3 FY2021 | Sep 30, 2021 | 4M | +15.3% |
| Q2 FY2021 | Jun 30, 2021 | 4M | +35.6% |
| Q1 FY2021 | Mar 31, 2021 | 4M | +49.4% |
| Q4 FY2020 | Dec 31, 2020 | 3M | +48.0% |
| Q3 FY2020 | Sep 30, 2020 | 3M | +47.8% |
| Q2 FY2020 | Jun 30, 2020 | 3M | +46.4% |
| Q1 FY2020 | Mar 31, 2020 | 2M | +32.7% |
| Q4 FY2019 | Dec 31, 2019 | 2M | +26.0% |
| Q3 FY2019 | Sep 30, 2019 | 2M | +21.0% |
| Q2 FY2019 | Jun 30, 2019 | 2M | +4.6% |
| Q1 FY2019 | Mar 31, 2019 | 2M | +16.5% |
| Q4 FY2018 | Dec 31, 2018 | 2M | +49.4% |
| Q3 FY2018 | Sep 30, 2018 | 2M | +49.0% |
| Q2 FY2018 | Jun 30, 2018 | 2M | +51.7% |
| Q1 FY2018 | Mar 31, 2018 | 2M | +36.3% |
| Q4 FY2017 | Dec 31, 2017 | 1M | +6.0% |
| Q3 FY2017 | Sep 30, 2017 | 1M | +5.8% |
| Q2 FY2017 | Jun 30, 2017 | 1M | – |
| Q1 FY2017 | Mar 31, 2017 | 1M | – |
| Q4 FY2016 | Dec 31, 2016 | 1M | – |
| Q3 FY2016 | Sep 30, 2016 | 1M | – |
See a number that looks wrong?